Canaccord analyst George Gianarikas initiated coverage of Kopin (KOPN) with a Buy rating and $2 price target The firm sees a “premium multiple” for the shares as justified “by several factors.” Kopin’s defense-related opportunities appear set for growth, particularly with several projects in the funded research and development stage, and the company is also seeing expanding application opportunities in the medical and consumer markets, the analyst tells investors in a research note. Canaccord believes Kopin’s “diverse market opportunities appear set to receive a material boost through its strategic initiatives to capture a growing share of wallet.” It also sees optionality, noting the company could look to expand either through targeted acquisitions or as an acquisition target itself.
Don't Miss Our New Year's Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KOPN:
- Kopin regains compliance with Nasdaq
- Kopin price target lowered to $2 from $2.50 at Ladenburg
- Kopin Corporation Reports Strong Revenue Growth in Q3 2024
- Kopin reports Q3 EPS (3c), consensus (4c)
- KOPN Earnings this Week: How Will it Perform?
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
